rs141853578

Variant names:

Variant summary

Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BS1_SupportingBS2

The NM_000204.5(CFI):c.355G>A(p.Gly119Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000763 in 1,613,848 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00038 ( 0 hom., cov: 32)

Exomes 𝑓: 0.00080 ( 3 hom. )

Consequence

CFI
NM_000204.5 missense

Scores

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:3U:5B:1O:2

Conservation

PhyloP100: 1.71

Variant links:

Genes affected

CFI (HGNC:5394): (complement factor I) This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this gene have been associated with a predisposition to atypical hemolytic uremic syndrome, a disease characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with immune deposits and age-related macular degeneration are other conditions associated with mutations of this gene. [provided by RefSeq, Dec 2015]

CFI links:

ENSG00000285330 (HGNC:):

ENSG00000285330 links:

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -5 ACMG points.

BS1

Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000381 (58/152142) while in subpopulation NFE AF= 0.000838 (57/68032). AF 95% confidence interval is 0.000664. There are 0 homozygotes in gnomad4. There are 23 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

BS2

High Homozygotes in GnomAdExome4 at 3 AD,AR gene

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
CFI	NM_000204.5 link	c.355G>A	p.Gly119Arg	missense_variant	Exon 3 of 13	ENST00000394634.7	NP_000195.3	P05156A8K3L0

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
CFI	ENST00000394634.7 link	c.355G>A	p.Gly119Arg	missense_variant	Exon 3 of 13	1	NM_000204.5	ENSP00000378130.2		P05156
ENSG00000285330	ENST00000645635.1 link	c.355G>A	p.Gly119Arg	missense_variant	Exon 3 of 15			ENSP00000493607.1		A0A2R8Y3M9

Frequencies

GnomAD3 genomes

AF:

0.000381

AC:

AN:

152142

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.0000241

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.00

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.000838

Gnomad OTH

AF:

0.00

GnomAD3 exomes

AF:

0.000422

AC:

106

AN:

251328

Hom.:

AF XY:

0.000456

AC XY:

AN XY:

135832

show subpopulations

Gnomad AFR exome

AF:

0.0000615

Gnomad AMR exome

AF:

0.0000578

Gnomad ASJ exome

AF:

0.0000992

Gnomad EAS exome

AF:

0.00

Gnomad SAS exome

AF:

0.00

Gnomad FIN exome

AF:

0.0000927

Gnomad NFE exome

AF:

0.000853

Gnomad OTH exome

AF:

0.000489

GnomAD4 exome

AF:

0.000802

AC:

1173

AN:

1461706

Hom.:

Cov.:

AF XY:

0.000776

AC XY:

564

AN XY:

727170

show subpopulations

Gnomad4 AFR exome

AF:

0.000149

Gnomad4 AMR exome

AF:

0.0000671

Gnomad4 ASJ exome

AF:

0.0000383

Gnomad4 EAS exome

AF:

0.00

Gnomad4 SAS exome

AF:

0.0000116

Gnomad4 FIN exome

AF:

0.0000375

Gnomad4 NFE exome

AF:

0.00102

Gnomad4 OTH exome

AF:

0.000414

GnomAD4 genome

AF:

0.000381

AC:

AN:

152142

Hom.:

Cov.:

AF XY:

0.000309

AC XY:

AN XY:

74332

show subpopulations

Gnomad4 AFR

AF:

0.0000241

Gnomad4 AMR

AF:

0.00

Gnomad4 ASJ

AF:

0.00

Gnomad4 EAS

AF:

0.00

Gnomad4 SAS

AF:

0.00

Gnomad4 FIN

AF:

0.00

Gnomad4 NFE

AF:

0.000838

Gnomad4 OTH

AF:

0.00

Alfa

AF:

0.00111

Hom.:

Bravo

AF:

0.000427

TwinsUK

AF:

0.000539

AC:

ALSPAC

AF:

0.000778

AC:

ESP6500AA

AF:

0.00

AC:

ESP6500EA

AF:

0.00128

AC:

ExAC

AF:

0.000527

AC:

EpiCase

AF:

0.000763

EpiControl

AF:

0.000948

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Pathogenic:3Uncertain:5Benign:1Other:2

Revision: criteria provided, conflicting classifications

LINK: link

Submissions by phenotype

not provided

Pathogenic:2Benign:1

Feb 18, 2022

GeneDx

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Published functional studies demonstrate reduced expression and activity (van de Ven et al., 2013); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20513133, 23685748, 26767664, 28637922, 28282489, 27939104, 27380463, 29398083, 29410599, 31528764, 31614353, 32510551, 32832254, 25352734, 24036952, 26691988, 29087762, 27918759, 29700787, 29888403, 29392637, 20203157, 32516404, 32195675, 33610747, 34153144, 34945728, 34169201) -

Jul 19, 2023

Mayo Clinic Laboratories, Mayo Clinic

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

PP4, PS3, PS4_moderate -

Jan 19, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Atypical hemolytic-uremic syndrome with I factor anomaly

Pathogenic:1Other:1

Nov 06, 2020

Victorian Clinical Genetics Services, Murdoch Childrens Research Institute

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Evidence in support of status as susceptibility allele: - Variant is present in gnomAD (v2) <0.001 for a dominant condition (120 heterozygotes, 0 homozygotes). - This variant has been reported as a susceptibility factor for aHUS and has been reported in patients with aHUS (PMIDs: 27177491, 20513133 and ClinVar). Additional information: - Loss of function in this gene is associated with susceptibility to atypical haemolytic uraemic syndrome (aHUS) 3 (MIM#612923). - This gene is associated with autosomal recessive complement factor I deficiency (MIM#610984). Monoallelic variants in this gene are associated with susceptibility to aHUS 3 (MIM#612923). - Variant is predicted to result in a missense amino acid change from glycine to arginine. - This variant is heterozygous. - Missense variant with conflicting in silico predictions and uninformative conservation. - Variant is located in the annotated CD5 domain (PMID: 20513133). - This variant has been shown to be maternally inherited (by trio analysis). -

Jul 01, 2013

OMIM

Significance: risk factor

Review Status: no assertion criteria provided

Collection Method: literature only

- -

not specified

Uncertain:2

Mar 04, 2025

Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Apr 10, 2024

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Variant summary: CFI c.355G>A (p.Gly119Arg) results in a non-conservative amino acid change located in the SRCR domain (IPR001190) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00076 in 1613848 control chromosomes, predominantly at a frequency of 0.001 within the Non-Finnish European subpopulation in the gnomAD database, including 3 homozygotes. This frequency is approximately equal to the maximum estimated frequency for a pathogenic variant in CFI causing Complement Factor I Deficiency ( 0.001 vs 0.0011) and is much higher than estimated for a pathogenic variant causing an autosomal dominant condition such as Atypical Hemolytic Uremic Syndrome, suggesting this variant may be benign. c.355G>A has been reported in the literature in the heterozygous state in multiple individuals affected with Atypical Hemolytic Uremic Syndrome and Age-related Macular Degeneration, without strong evidence for pathogenicity (i.e. segregation data) and has also been reported in healthy controls (e.g. Maga_2010, van de Ven_2013, de Jong_2020, Zhang_2022). It has been reported in at least two presumably compound heterozygous individuals (phase unspecified) with Atypical Hemolytic Uremic Syndrome/C3 glomerulopathy who were not described as having clinical features of Complement Factor I Deficiency (e.g. Maga_2010, Zhang_2022) and to our knowledge, this variant has not been reported in individuals with this condition. These reports do not provide unequivocal conclusions about association of the variant with disease. At least two publications report experimental evidence evaluating an impact on protein function (van de Ven_2013, de Jong_2020). The variant results in decreased expression and secretion in vitro, but has a higher efficiency versus the WT protein. Heterozygous carriers of the variant have been found to have reduced FI plasma levels, at approximately 55-60% of normal, however the clinical significance of this with respect to disease manifestation is unclear (de Jong_2020). The following publications have been ascertained in the context of this evaluation (PMID: 20513133, 35619721, 32510551, 23685748). ClinVar contains an entry for this variant (Variation ID: 66014). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. -

Factor I deficiency

Uncertain:1

May 28, 2021

Baylor Genetics

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Atypical hemolytic-uremic syndrome with I factor anomaly;C3463916:Factor I deficiency;C3809523:Age related macular degeneration 13

Uncertain:1

Feb 02, 2024

Fulgent Genetics, Fulgent Genetics

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Atypical hemolytic-uremic syndrome

Uncertain:1

Feb 21, 2019

Sydney Genome Diagnostics, Children's Hospital Westmead

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

This individual is heterozygous for the c.355G>A variant in the CFI gene, which results in the amino acid substitution of glycine to arginine at residue 119, p.(Gly119Arg). This variant has been reported in the gnomAD browser (http://gnomad.broadinstitute.org) with an allele frequency of 0.09% (110 out of 129,124 alleles) in the European non-Finnish population. This variant has been reported in the Database of complement gene variants (https://www.complement-db.org/home.php) as a VOUS in 16 individuals with aHUS with and without a second variant in CFI or another complement gene. p.Gly119Arg has been reported in ClinVar as a VOUS (variation ID 66014). p.Gly119Arg has also been reported to confer high risk of developing age-related macular degeneration (ARMD) (van de Ven et al 2013 Nat Genet 45:813-817 and Fritsche et al 2016 Nat Genet. 48:134-143). In vitro functional studies were performed by van de Ven et al 2013 and showed that the Gly119Arg mutant protein resulted in lower levels of expression and secretion compared to wild-type protein. This variant is considered to be a variant of uncertain clinical significance (VOUS) according to the ACMG guidelines (Evidence used: PS3). -

Macular degeneration, age-related, 13, susceptibility to

Other:1

Jul 01, 2013

OMIM

Significance: risk factor

Review Status: no assertion criteria provided

Collection Method: literature only

- -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Benign

0.19

BayesDel_addAF

Benign

-0.16

BayesDel_noAF

Uncertain

-0.080

CADD

Benign

DANN

Uncertain

1.0

DEOGEN2

Benign

0.27

.;T;T;T;.;.

Eigen

Uncertain

0.25

Eigen_PC

Benign

0.079

FATHMM_MKL

Benign

0.14

LIST_S2

Benign

0.81

T;T;T;T;T;T

M_CAP

Benign

0.040

MetaRNN

Benign

0.091

T;T;T;T;T;T

MetaSVM

Benign

-0.49

MutationAssessor

Pathogenic

3.6

.;H;.;.;.;.

PrimateAI

Benign

0.40

PROVEAN

Uncertain

-3.2

.;D;D;.;D;D

REVEL

Uncertain

0.32

Sift

Uncertain

0.0090

.;D;D;.;D;D

Sift4G

Benign

0.15

.;T;T;D;T;T

Polyphen

0.98, 0.97, 0.94

.;D;D;.;P;.

Vest4

0.40, 0.38, 0.55, 0.38, 0.19

MutPred

0.93

Gain of solvent accessibility (P = 0.1319);Gain of solvent accessibility (P = 0.1319);Gain of solvent accessibility (P = 0.1319);Gain of solvent accessibility (P = 0.1319);Gain of solvent accessibility (P = 0.1319);Gain of solvent accessibility (P = 0.1319);

MVP

0.73

MPC

0.11

ClinPred

0.14

GERP RS

5.6

Varity_R

0.45

gMVP

0.67

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.35

Details are displayed if max score is > 0.2

DS_AL_spliceai

0.35

Position offset: 26

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

LitVar

Other links and lift over